Results 201 to 210 of about 10,714,680 (266)

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Lauren classification-based combined model integrating clinicopathological and spectral CT features for disease-free survival prediction in gastric cancer. [PDF]

Cancer Imaging
You H, Ren T, Xu M, Chen Q, Ma L, Peng Y, Zhang C, Liu X, Zhang W.   +8 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group. [PDF]

BMC Cancer
Seyyar M, Şancı PC, Doğan A, Biter S, Köşeci T, Balçık OY, Karabel SS, Kalem A, Akosman C, Pilancı KN, Onur İD, Arslan ÜY, Kemal Y, Avcı T, Şahbazlar M, Akay S, Kahraman EG, Bayramgil A, Altıntaş YE, Tünbekici S, Göker E, Çolak C, Demir T, Demirağ G, Güneysu GG, Aykan MB, Nazlı İ, Alkan O, Ökten İN, Çolak R, Yılmaz M, Gür HB, Hacıbekiroğlu İ, Sönmez M, Özyurt N, Aydın O, Ertürk K, Şahin E, Karakayalı A, Baydar E, Çıtakkul İ, Emin G, Yıldırım A, Gülmez A, Özberk U, Algın E, Köseoğlu Ç, Uzundere FK, Urakçı Z, Akpunar M, Alkan A, Süner A, Peker P, Camadan YA, Can LŞ, Telli TA, Majidova N, Uzun M, Özkan MK, Baykara M, Güzel HG, Yıldırım HÇ, Kefeli U, Çabuk D, Kus T.   +64 more
europepmc   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast. [PDF]

Front Oncol
Zhang T, Guo Y, Li X, Xie L.
europepmc   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters. [PDF]

Clin Transl Radiat Oncol
Giannetta C, Nebbache R, Etienney I, Goujon G, Aparicio T, Maggiori L, Abramowitz L, Quéro L.   +7 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

An integrated multimodal model for early prediction of high-risk recurrence phenotype indicative of poor disease-free survival in stage IA NSCLC: a multicenter study. [PDF]

Front Immunol
Lai L, Wang Y, Jiang J, Yang D, Wu J, Xie L, Wu J, Mao R, Zhang D, Wang X, Ming W, Tu J.   +11 more
europepmc   +1 more source